

Ref: ADL/SE/2025-26/39
September 4, 2025

To,
 Listing/ Compliance Department
BSE Limited
 Phiroze Jeejeebhoy Towers,
 Dalal Street,
 Mumbai – 400 001
BSE CODE: 524348

To,
 Listing/ Compliance Department
National Stock Exchange of India Limited,
 “Exchange Plaza”, Plot No. C/1,
 G Block Bandra - Kurla Complex,
 Bandra (East), Mumbai – 400051
NSE SYMBOL: AARTIDRUGS

Dear Sir/Madam,

Sub: Commercialization of manufacturing Plant located at Sayakha
Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

With reference to the captioned subject, we wish to inform you that Company’s new manufacturing plant situated at Sayakha, Gujarat has commenced the Commercial Production/ Commercial Operations w.e.f. September 4, 2025.

The requisite information as per Para B of Part A of Schedule III under Regulation 30 of the Listing Regulations read with SEBI circular No. SEBI/HO /CFD/PoD2/CIR/P/0155 dated November 11, 2024 is given below:

Existing capacity	Nil (This is new manufacturing plant)
Existing capacity utilization	Nil (This is new manufacturing plant)
Proposed capacity addition	60 MTPd
period within which the proposed capacity is to be added	Currently, capacity utilization will be approximately one third of its total capacity. Plant will become fully operational over next 12 to 18 months
investment required	Company have invested around Rs. 220 Crores
mode of financing	Combination of term loan and internal accruals
name of the product	Dimethylamine (DMA), Monomethylamine (MMA), Trimethylamine (TMA) and derivatives
date of launch	Commercial operation has started w.e.f. September 4, 2025
category of the product	Spec chem and Intermediate



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

whether caters to domestic/ international market	Above products will cater the domestic demand at first and with growing opportunities, company shall extend its reach to export markets based on potential.
name of the countries in which the product is launched (in case of international).	Not applicable
Rationale	For backward integration to reduce the reliance on external raw materials, thereby enhancing supply chain reliability and to drive incremental margin expansion as well as for positioning for sustained success in the future.

This is for your information and records.

Thanking you,

Yours faithfully,

FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE
COMPANY SECRETARY & COMPLIANCE OFFICER
ICSI M. No.: F12932